Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First
Executive Summary
Sage Therapeutics is on track to deliver the first ever drug to be indicated for postpartum depression. The company discusses plans for launch and whether or not it wants to partner.
You may also be interested in...
All Smiles At Sage As Phase III Postpartum Depression Data Are Positive
The company plans to file an NDA with FDA in the first half of 2018 for an intravenous formulation of brexanolone, which could be the first treatment specifically for postpartum depression.
Sage Says Brexanolone's SRSE Result Doesn't Mean PPD Studies Will Fail
The Phase III study for brexanolone in super-refractory status epilepticus did not meet its primary endpoint, but Sage is optimistic about the drug's prospects in postpartum depression and its earlier-stage SAGE-217.
Sage Drug Could Help Take Stigma Out Of Postpartum Depression
SAGE Therapeutics Inc. could offer the one in eight new mothers suffering from postpartum depression (PPD) freedom from the overwhelming condition with the first-ever drug to specifically treat PPD if the rapid and durable response to SAGE-547 in a small Phase II clinical trial holds up in future studies.